[{"Abstract":"Abstract is embargoed at this time.","Actions":[{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Late Breaking and Clinical Trials","AdditionalFields":[{"Key":"Topics","Value":"++CT06-01 Phase III adult clinical trials,,"},{"Key":"Keywords","Value":"Glioblastoma,Anti-PD-1,Nivolumab,Cancer immunotherapy,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":null,"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":"<b>Y.-H. Hung<\/b><sup>1<\/sup>, A. Chhibber<sup>1<\/sup>, M. Lim<sup>2<\/sup>, M. Weller<sup>3<\/sup>, D. A. Reardon<sup>4<\/sup>, A. Omuro<sup>5<\/sup>, K. L. Ligon<sup>6<\/sup>, A. Lako<sup>1<\/sup>, A. Forslund<sup>1<\/sup>; <br\/><sup>1<\/sup>Bristol Myers Squibb, Princeton, NJ, <sup>2<\/sup>Stanford University School of Medicine, Palo Alto, CA, <sup>3<\/sup>University Hospital Zürich, Zürich, Switzerland, <sup>4<\/sup>Dana-Farber\/Harvard Cancer Center, Boston, MA, <sup>5<\/sup>Yale Cancer Center, Yale University, New Haven, CT, <sup>6<\/sup>Dana-Farber\/Brigham and Women’s Cancer Center, Boston, MA","CSlideId":"","ControlKey":"c3964097-1eba-489b-bc51-6d8ed1abfd95","ControlNumber":"10756","DisclosureBlock":"<b>&nbsp;Y. Hung, <\/b> <br><b>Bristol Myers Squibb<\/b> Employment, Stock. <br><b>A. Chhibber, <\/b> <br><b>Bristol Myers Squibb<\/b> Employment, Stock.<br><b>M. Lim, <\/b> None.&nbsp;<br><b>M. Weller, <\/b> <br><b>Quercis<\/b> Grant\/Contract. <br><b>Versameb<\/b> Grant\/Contract. <br><b>Bayer<\/b> Other, Advisory. <br><b>Curevac<\/b> Other, Data safety monitoring board. <br><b>Medac<\/b> Other, Advisory. <br><b>Neurosense<\/b> Other, Advisory. <br><b>Novartis<\/b> Other, Advisory. <br><b>Novocure<\/b> Other, Speaker. <br><b>Orbus<\/b> Other, Data safety monitoring board. <br><b>Philogen<\/b> Other, Data safety monitoring board. <br><b>Roche<\/b> Other, Advisory. <br><b>Servier<\/b> Other, Advisory. <br><b>D. A. Reardon, <\/b> <br><b>Abbvie; Advantagene; Agenus; Agios; Amgen; Avita Biomedical, Inc., Bayer; Blue Rock Therapeutics; Boston Biomedical; Boehringer Ingelheim; Bristol-Myers Squibb; CeCava; Celldex; Deciphera; DelMar<\/b> Other, Advisory board and\/or consulting. <br><b>Ellipses Pharma; EMD Serono; Genenta; Genentech\/Roche; Imvax; Inovio; Kintara; Kiyatec; Medicenna Biopharma, Inc.<\/b> Other, Advisory board and\/or consulting. <br><b>Merck; Merck KGaA; Monteris; Neuvogen; Novartis; Novocure; Oncorus; Oxigene; Regeneron; Stemline; Sumitono Dainippon Pharma; Taiho Oncology, Inc.<\/b> Other, Advisory board and\/or consulting. <br><b>A. Omuro, <\/b> <br><b>KIYATEC<\/b> Other, Consultant on ad hoc advisory boards. <br><b>Merck<\/b> Other, Consultant on ad hoc advisory boards. <br><b>Pyramid<\/b> Other, Consultant on ad hoc advisory boards. <br><b>Ono Pharmaceutical Company Ltd.<\/b> Other, Consultant on ad hoc advisory boards. <br><b>Agios<\/b> Grant\/Contract. <br><b>Arcus Biosciences<\/b> Grant\/Contract. <br><b>Denovo<\/b> Grant\/Contract. <br><b>K. L. Ligon, <\/b> <br><b>Travera<\/b> Independent Contractor, Stock. <br><b>Bristol Myers Squibb<\/b> Independent Contractor. <br><b>Blaze Bioscience<\/b> Independent Contractor. <br><b>Integragen<\/b> Independent Contractor. <br><b>A. Lako, <\/b> <br><b>Bristol Myers Squibb<\/b> Employment, Stock. <br><b>A. Forslund, <\/b> <br><b>Bristol Myers Squibb<\/b> Employment, Stock.","End":"4\/9\/2024 12:30:00 PM","HasWebcast":null,"Highlights":[],"Id":"11590","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":null,"OtherContent":null,"PlayerUrl":"https:\/\/files.abstractsonline.com\/SUPT\/101\/10517\/cfg-cattendee-cslide-player-view-content-embargoed.png","PlayerUrlReason":"Content is embargoed at this time.","PositionInSession":"1","PosterboardNumber":"1","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"CT230","PresenterBiography":null,"PresenterDisplayName":"Yu-Han Hung","PresenterKey":"5b6a5ce4-8d6e-4fc2-b735-c942035cb5f3","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"CT230. Exploratory analyses of MGMT promoter methylation and PD-L1 expression from newly diagnosed glioblastoma patients in CheckMate 548 study suggest refinement in thresholds for predicting response to standard of care and nivolumab treatments","SearchResultFooter":"","SearchResultHeader":"Apr  9 2024  9:00AM","SessionId":"618","SessionOnDemand":"False","SessionTitle":"Phase III Clinical Trials","ShowChatLink":"false","Start":"4\/9\/2024 9:00:00 AM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"Exploratory analyses of MGMT promoter methylation and PD-L1 expression from newly diagnosed glioblastoma patients in CheckMate 548 study suggest refinement in thresholds for predicting response to standard of care and nivolumab treatments","Topics":null,"cSlideId":""},{"Abstract":"Abstract is embargoed at this time.","Actions":[{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Late Breaking and Clinical Trials","AdditionalFields":[{"Key":"Topics","Value":"++CT06-01 Phase III adult clinical trials,,"},{"Key":"Keywords","Value":"PARP inhibitors,Prostate cancer,Cancer genomics,,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":null,"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":"<b>G. Liu<\/b><sup>1<\/sup>, X. Mu<sup>2<\/sup>, K. Fizazi<sup>3<\/sup>, A. Laird<sup>2<\/sup>, N. Matsubara<sup>4<\/sup>, S. M. Yip<sup>5<\/sup>, J. Pu<sup>6<\/sup>, J. Carles<sup>7<\/sup>, A. P. Fay<sup>8<\/sup>, R. J. Jones<sup>9<\/sup>, S. Zschäbitz<sup>10<\/sup>, J. M. Piulats<sup>11<\/sup>, J. Young Joung<sup>12<\/sup>, W. Roh<sup>2<\/sup>, J. Chelliserry<sup>2<\/sup>, N. Di Santo<sup>13<\/sup>, M. Saul<sup>2<\/sup>, A. A. Azad<sup>14<\/sup>, N. Agarwal<sup>15<\/sup>; <br\/><sup>1<\/sup>Carbone Cancer Center, University of Wisconsin, Madison, WI, <sup>2<\/sup>Pfizer Inc., La Jolla, CA, <sup>3<\/sup>Institut Gustave Roussy, University of Paris-Saclay, Villejuif, France, <sup>4<\/sup>National Cancer Center Hospital East, Chiba, Japan, <sup>5<\/sup>Tom Baker Cancer Centre and Cumming School of Medicine, Calgary, AB, Canada, <sup>6<\/sup>Pfizer Inc., Remote, AZ, <sup>7<\/sup>Vall d’Hebron University Hospital, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain, <sup>8<\/sup>PUCRS School of Medicine, Porto Alegre, Brazil, <sup>9<\/sup>School of Cancer Sciences, University of Glasgow, Beatson West of Scotland Cancer Centre, Glasgow, United Kingdom, <sup>10<\/sup>National Center for Tumor Diseases (NCT), Heidelberg University Hospital, Heidelberg, Germany, <sup>11<\/sup>Institut Català d’Oncologia–Bellvitge Institute for Biomedical Research, Barcelona, Spain, <sup>12<\/sup>National  Cancer Center, Goyang, Korea, Republic of, <sup>13<\/sup>Formerly of Pfizer Inc., Durham, NC, <sup>14<\/sup>Peter MacCallum Cancer Centre, Melbourne, Australia, <sup>15<\/sup>Huntsman Cancer Institute (NCI-CCC), University of Utah, Salt Lake City, UT","CSlideId":"","ControlKey":"f01f0b28-0b35-468e-aef7-ef20920518df","ControlNumber":"10323","DisclosureBlock":"&nbsp;<b>G. Liu, <\/b> None.&nbsp;<br><b>X. Mu, <\/b> <br><b>Pfizer Inc<\/b> Employment, Stock, Stock Option. <br><b>K. Fizazi, <\/b> <br><b>Advanced Accelerator Applications\/Novartis; Amgen; Astellas Pharma; AstraZeneca; Bayer; Clovis Oncology; Daiichi Sankyo; Janssen; MSD; Novartis; Pfizer; Sanofi<\/b> Other, honoraria (institution) for participation in advisory boards and talks. <br><b>Arvinas; CureVac; MacroGenics; Orion<\/b> Other, honoraria (personal) for participation in advisory boards. <br><b>A. Laird, <\/b> <br><b>Pfizer<\/b> Employment, Stock, Stock Option. <br><b>N. Matsubara, <\/b> <br><b>Sanofi<\/b> Other, honoraria (personal). <br><b>Amgen; Astellas Pharma; AstraZeneca; Bayer; Chugai Pharma; Eisai; Janssen; Lilly; MSD; Pfizer; PRA Health Science; Roche; Seagen; Taiho; Takeda<\/b> Other, research funding (institution). <br><b>Pfizer<\/b> Travel. <br><b>S. M. Yip, <\/b> <br><b>Amgen; Astellas Pharma; AstraZeneca; Merck; Bayer; Bristol Myers Squibb; Novartis; Pfizer; Hoffmann-La Roche; Ipsen; Janssen; OncoHelix<\/b> Other, consultancy or advisory role and honoraria. <br><b>J. Pu, <\/b> <br><b>Pfizer Inc<\/b> Employment, Stock, Stock Option. <br><b>J. Carles, <\/b> <br><b>Advanced Accelerator Applications\/Novartis; Astellas Pharma, AstraZeneca, Bayer, Bristol Myers Squibb; Johnson & Johnson; MSD Oncology; Pfizer; Roche; Sanofi<\/b> Other, consulting or advisory role. <br><b>Astellas Pharma; Bayer; Johnson & Johnson<\/b> Other, participation in speakers’ bureau. <br><b>AB Science; Aragon Pharmaceuticals; AROG Pharmaceuticals; Astellas Pharma; AstraZeneca AB; AVEO Pharmaceuticals; Bayer AG; Blueprint Medicines; BN ImmunoTherapeutics; Boehringer Ingelheim España SA<\/b> Other, research funding (institution). <br><b>Bristol Myers Squibb International Corporation; Clovis Oncology; Cougar Biotechnology; Deciphera; Exelixis; Genentech; GlaxoSmithKline; Incyte; Janssen-Cilag International NV; Karyopharm Therapeutics<\/b> Other, research funding (institution). <br><b>Laboratoires Leurquin Mediolanum; Lilly; MedImmune; Millennium Pharmaceuticals; Nanobiotix; Novartis Farmacéutica SA; Pfizer; Puma Biotechnology; Roche; Sanofi Aventis GmbH; SFJ Pharmaceuticals Group<\/b> Other, research funding (institution). <br><b>Teva<\/b> Other, research funding (institution). <br><b>AstraZeneca; BMS; Ipsen; Roche<\/b> Travel. <br><b>A. P. Fay, <\/b> <br><b>Astellas Pharma; AstraZeneca; Bristol Myers Squibb; Ipsen; Janssen; MSD; Novartis; Pfizer; Roche<\/b> Other, honoraria. <br><b>Bayer; Ipsen; Janssen; MSD; Novartis; Pfizer; Roche<\/b> Other, consulting or advisory role. <br><b>Brazilian Information Oncology<\/b> Stock, Stock Option. <br><b>AstraZeneca; Bristol Myers Squibb; CAPES – CNPq; Foundation Medicine; Ipsen; MSD; Roche<\/b> Other, research funding. <br><b>Astellas Pharma; AstraZeneca; BMS; Ipsen; Janssen; MSD; Novartis; Pfizer; Roche<\/b> Travel. <br><b>R. J. Jones, <\/b> <br><b>Astellas Pharma; Bayer; Bristol Myers Squibb; Ipsen; Janssen; Merck Serono; MSD; Pfizer; Roche<\/b> Other, honoraria. <br><b>Astellas Pharma; Bayer; Bristol Myers Squibb; Ipsen; Janssen; Merck Serono; MSD; Novartis; Pfizer; Roche<\/b> Other, consulting or advisory role. <br><b>Astellas Pharma; Bayer; Clovis Oncology; Exelixis; Roche<\/b> Other, research funding. <br><b>Bayer; Janssen<\/b> Travel. <br><b>S. Zschäbitz, <\/b> <br><b>Amgen; Astellas; Bayer; Bristol Myers Squibb; Merck Serono; Pfizer<\/b> Other, personal and institutional payment or honoraria for lectures, presentations, speakers’ bureaus, manuscript writing, or educational events. <br><b>Eisai; Janssen; Novartis<\/b> Other, personal payment or honoraria for lectures, presentations, speakers’ bureaus, manuscript writing, or educational events. <br><b>Amgen; Bayer; Merck Serono<\/b> Other, personal and institutional participation on a data safety monitoring board or advisory board. <br><b>Eisai; Gilead; Ipsen; Janssen; Novartis<\/b> Other, personal participation on a data safety monitoring board or advisory board. <br><b>Bristol Myers Squibb; MSD; Pfizer<\/b> Other, Institutional participation on a data safety monitoring board or advisory board. <br><b>Eisai<\/b> Other, Institutional research funding. <br><b>Amgen; Astellas Pharma; AstraZeneca; Bayer; Ipsen; Janssen; Merck Serono; MSD; Pfizer<\/b> Travel. <br><b>MSD<\/b> Other, Institutional payment or honororia for lectures, presentations, speakers' bureaus, manuscript writing, or educational events. <br><b>J. M. Piulats, <\/b> <br><b>Advanced Accelerator Applications\/Novartis; Astellas Pharma; AstraZeneca; Bayer; BeiGene; Bristol Myers Squibb; Clovis; Janssen; MSD Oncology; Pfizer; Roche; Sanofi<\/b> Other, consulting or advisory role. <br><b>BeiGene; BMS; Janssen; Merck Serono; Mirati; MSD; Pfizer<\/b> Other, research funding. <br><b>AstraZeneca; Pfizer<\/b> Travel.<br><b>J. Young Joung, <\/b> None.&nbsp;<br><b>W. Roh, <\/b> <br><b>Pfizer Inc<\/b> Employment, Stock, Stock Option. <br><b>J. Chelliserry, <\/b> <br><b>Pfizer Inc<\/b> Employment, Stock, Stock Option. <br><b>N. Di Santo, <\/b> <br><b>Pfizer Inc<\/b> Other, Former employment. <br><b>M. Saul, <\/b> <br><b>Pfizer Inc<\/b> Employment, Stock, Stock Option. <br><b>A. A. Azad, <\/b> <br><b>Aculeus Therapeutics, Amgen, Astellas Pharma, AstraZeneca, Bayer, Bristol Myers Squibb, Daiichi Sankyo, Ipsen, Janssen, Merck Serono, Merck Sharp & Dohme, Novartis, Noxopharm, Pfizer, Sanofi<\/b> Other, honoraria. <br><b>Telix Pharmaceuticals; Tolmar<\/b> Other, honoraria. <br><b>Amgen; Arvinas; Astellas Pharma; AstraZeneca; Bayer; Bristol Myers Squibb; Daiichi Sankyo; Ipsen; Janssen; Merck Serono; Merck Sharp & Dohme; Novartis; Noxopharm; Pfizer; Sanofi; Telix; Tolmar<\/b> Other, participation on advisory boards. <br><b>OncoSec<\/b> Other, participation on a data safety monitoring board. <br><b>Aptevo Therapeutics; Astellas Pharma; AstraZeneca; Bionomics; Bristol Myers Squibb; Exelixis; Gilead Sciences; GlaxoSmithKline; Hinova Pharmaceuticals; Ipsen; Janssen; Lilly; MedImmune; Merck Serono<\/b> Other, research funding. <br><b>MSD; Novartis; Pfizer; Sanofi; Synthorx<\/b> Other, research funding. <br><b>Amgen; Astellas Pharma; Janssen; Merck Serono; Novartis; Pfizer; Tolmar<\/b> Travel. <br><b>Astellas Pharma; Exelixis; Pfizer<\/b> Other, receiving medical writing services. <br><b>Clinical Oncology Society of Australia<\/b> Other, Chair of the Urologic Oncology Group. <br><b>ANZUP Cancer Trials Group<\/b> Other, Chair of the Translational Research Subcommittee and on the Scientific Advisory Committee. <br><b>Aculeus Therapeutics; Astellas Pharma; Janssen; Novartis<\/b> Other, consulting fees. <br><b>N. Agarwal, <\/b> <br><b>Astellas Pharma; AstraZeneca; AVEO; Bayer; Bristol Myers Squibb; Calithera Biosciences; Eisai; EMD Serono; Exelixis; Foundation Medicine; Genentech; Gilead Sciences; Immunomedics; Janssen; Lilly<\/b> Other, honorarium for consultancy before May 2021. <br><b>MEI Pharma<\/b> Other, honorarium for consultancy before May 2021. <br><b>Arvinas; Astellas Pharma; AstraZeneca; Bayer; Bristol Myers Squibb; Calithera Biosciences; Celldex; Clovis Oncology; CRISPR Therapeutics; Eisai; EMD Serono; Exelixis; Genentech; Gilead Sciences<\/b> Other, research funding (institution). <br><b>GlaxoSmithKline; Immunomedics; Janssen; Lava; Lilly; Merck; Nektar; Neoleukin; Novartis; ORIC Pharmaceuticals; Pfizer; Rexahn; Roche; Sanofi; Seagen; Takeda; TRACON<\/b> Other, research funding (institution).","End":"4\/9\/2024 12:30:00 PM","HasWebcast":null,"Highlights":[],"Id":"11591","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":null,"OtherContent":null,"PlayerUrl":"https:\/\/files.abstractsonline.com\/SUPT\/101\/10517\/cfg-cattendee-cslide-player-view-content-embargoed.png","PlayerUrlReason":"Content is embargoed at this time.","PositionInSession":"2","PosterboardNumber":"2","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"CT231","PresenterBiography":null,"PresenterDisplayName":"Olivia Clift","PresenterKey":"08f59abf-deb9-47e5-909f-c35aeac57707","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"CT231. Identification of a novel agnostic predictive multiomic signature via Elastic Net\/Machine Learning in TALAPRO-2 (TP-2), a phase 3 study of talazoparib (TALA) + enzalutamide (ENZA) vs placebo (PBO) + ENZA as first-line (1L) treatment in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC)","SearchResultFooter":"","SearchResultHeader":"Apr  9 2024  9:00AM","SessionId":"618","SessionOnDemand":"False","SessionTitle":"Phase III Clinical Trials","ShowChatLink":"false","Start":"4\/9\/2024 9:00:00 AM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"Identification of a novel agnostic predictive multiomic signature via Elastic Net\/Machine Learning in TALAPRO-2 (TP-2), a phase 3 study of talazoparib (TALA) + enzalutamide (ENZA) vs placebo (PBO) + ENZA as first-line (1L) treatment in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC)","Topics":null,"cSlideId":""},{"Abstract":"Abstract is embargoed at this time.","Actions":[{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Late Breaking and Clinical Trials","AdditionalFields":[{"Key":"Topics","Value":"++CT06-01 Phase III adult clinical trials,,"},{"Key":"Keywords","Value":"Exercise,Prostate cancer,Survival,,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":null,"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":"<b>S. A. Kenfield<\/b><sup>1<\/sup>, N. H. Hart<sup>2<\/sup>, J. Sison<sup>1<\/sup>, J. M. Chan<sup>1<\/sup>, K. S. Courneya<sup>3<\/sup>, F. Saad<sup>4<\/sup>, R. U. Newton<sup>5<\/sup>; <br\/><sup>1<\/sup>UCSF - University of California San Francisco, San Francisco, CA, <sup>2<\/sup>University of Technology Sydney, Sydney, Australia, <sup>3<\/sup>University of Alberta, Edmonton, AB, Canada, <sup>4<\/sup>Université de Montréal, Montréal, QC, Canada, <sup>5<\/sup>Edith Cowan University, Perth, Australia","CSlideId":"","ControlKey":"c397634b-f8a9-4433-807f-3b2fb31b8179","ControlNumber":"10832","DisclosureBlock":"<b>&nbsp;S. A. Kenfield, <\/b> <br><b>Fellow Health<\/b> Independent Contractor, Stock Option. <br><b>Veracyte<\/b> Grant\/Contract.<br><b>N. H. Hart, <\/b> None..<br><b>J. Sison, <\/b> None.&nbsp;<br><b>J. M. Chan, <\/b> <br><b>Veracyte<\/b> Grant\/Contract. <br><b>Adela, Inc.<\/b> Other, Spouse employed by Adela.<br><b>K. S. Courneya, <\/b> None..<br><b>F. Saad, <\/b> None..<br><b>R. U. Newton, <\/b> None.","End":"4\/9\/2024 12:30:00 PM","HasWebcast":null,"Highlights":[],"Id":"11592","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":null,"OtherContent":null,"PlayerUrl":"https:\/\/files.abstractsonline.com\/SUPT\/101\/10517\/cfg-cattendee-cslide-player-view-content-embargoed.png","PlayerUrlReason":"Content is embargoed at this time.","PositionInSession":"3","PosterboardNumber":"3","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"CT232","PresenterBiography":null,"PresenterDisplayName":"Stacey Kenfield","PresenterKey":"1a17be4b-f0ec-4c0f-978a-2f8fc250f06f","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"CT232. Intense exercise for survival among men with metastatic prostate cancer: 12-month feasibility results from the INTERVAL-GAP4 trial pilot site at Edith Cowan University, Australia","SearchResultFooter":"","SearchResultHeader":"Apr  9 2024  9:00AM","SessionId":"618","SessionOnDemand":"False","SessionTitle":"Phase III Clinical Trials","ShowChatLink":"false","Start":"4\/9\/2024 9:00:00 AM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"Intense exercise for survival among men with metastatic prostate cancer: 12-month feasibility results from the INTERVAL-GAP4 trial pilot site at Edith Cowan University, Australia","Topics":null,"cSlideId":""},{"Abstract":"Abstract is embargoed at this time.","Actions":[{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Late Breaking and Clinical Trials","AdditionalFields":[{"Key":"Topics","Value":"++CT06-01 Phase III adult clinical trials,,"},{"Key":"Keywords","Value":"Prostate cancer,Thymidine kinase,Metastatic tumors,Recurrence,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":null,"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":"A. Siltari<sup>1<\/sup>, P. Raittinen<sup>2<\/sup>, J. Riikonen<sup>3<\/sup>, J. Koskimäki<sup>3<\/sup>, T. Pakarainen<sup>3<\/sup>, M. Anttinen<sup>4<\/sup>, O. Ettala<sup>5<\/sup>, T. Tammela<sup>1<\/sup>, S. Linder<sup>6<\/sup>, <b>T. J. Murtola<\/b><sup>1<\/sup>; <br\/><sup>1<\/sup>University of Tampere, Tampere, Finland, <sup>2<\/sup>Aalto University, Helsinki, Finland, <sup>3<\/sup>TAYS Cancer Center, Tampere, Finland, <sup>4<\/sup>Turku University Hospital, Turku, Finland, <sup>5<\/sup>University of Turku, Turku, Finland, <sup>6<\/sup>Arocell ab, Stockholm, Sweden","CSlideId":"","ControlKey":"1576d3b1-10cc-4344-964a-b82abe489d6f","ControlNumber":"10609","DisclosureBlock":"<b>&nbsp;A. Siltari, <\/b> <br><b>Janssen<\/b> Other, lecture fee. <br><b>P. Raittinen, <\/b> <br><b>Oriola<\/b> Employment.<br><b>J. Riikonen, <\/b> None..<br><b>J. Koskimäki, <\/b> None..<br><b>T. Pakarainen, <\/b> None..<br><b>M. Anttinen, <\/b> None..<br><b>O. Ettala, <\/b> None..<br><b>T. Tammela, <\/b> None.&nbsp;<br><b>S. Linder, <\/b> <br><b>Arocell<\/b> Employment. <br><b>T. J. Murtola, <\/b> <br><b>Merck<\/b> Other, Lecture fee. <br><b>Janssen<\/b> Grant\/Contract, Other, lecture fee. <br><b>Sanofi<\/b> Other, lecture fee. <br><b>Bayer<\/b> Grant\/Contract, Other, lecture fee. <br><b>Roche<\/b> Other, lecture fee. <br><b>Pfizer<\/b> Grant\/Contract, lecture fee. <br><b>Ipsen<\/b> Other, lecture fee. <br><b>Astellas<\/b> Grant\/Contract, Other, lecture fee. <br><b>Amgen<\/b> Grant\/Contract, Other, lecture fee. <br><b>Orion pharma<\/b> Grant\/Contract. <br><b>MSD<\/b> Grant\/Contract. <br><b>Arocell<\/b> Independent Contractor, Grant\/Contract.","End":"4\/9\/2024 12:30:00 PM","HasWebcast":null,"Highlights":[],"Id":"11593","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":null,"OtherContent":null,"PlayerUrl":"https:\/\/files.abstractsonline.com\/SUPT\/101\/10517\/cfg-cattendee-cslide-player-view-content-embargoed.png","PlayerUrlReason":"Content is embargoed at this time.","PositionInSession":"4","PosterboardNumber":"4","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"CT233","PresenterBiography":null,"PresenterDisplayName":"Teemu Murtola, MD;PhD","PresenterKey":"74a61eae-ca25-413b-aad7-04ab52b11e99","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"CT233. Serum thymidine kinase 1 levels as a predictive marker for castration resistance in metastatic prostate cancer","SearchResultFooter":"","SearchResultHeader":"Apr  9 2024  9:00AM","SessionId":"618","SessionOnDemand":"False","SessionTitle":"Phase III Clinical Trials","ShowChatLink":"false","Start":"4\/9\/2024 9:00:00 AM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"Serum thymidine kinase 1 levels as a predictive marker for castration resistance in metastatic prostate cancer","Topics":null,"cSlideId":""},{"Abstract":"Abstract is embargoed at this time.","Actions":[{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Late Breaking and Clinical Trials","AdditionalFields":[{"Key":"Topics","Value":"++CT06-01 Phase III adult clinical trials,,"},{"Key":"Keywords","Value":"RNA sequencing (RNA-Seq),PD-L1,Tumor microenvironment,Immune cells,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":null,"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":"<b>C. Zhou<\/b><sup>1<\/sup>, C. Sun<sup>2<\/sup>, S. Huang<sup>2<\/sup>, X. Dong<sup>3<\/sup>, G. Chen<sup>4<\/sup>, Z. Wang<sup>5<\/sup>, X. Wu<sup>6<\/sup>, Y. Yao<sup>7<\/sup>, Y. Zhang<sup>8<\/sup>, Y. Cheng<sup>9<\/sup>, H. Pan<sup>10<\/sup>, X. Zhang<sup>11<\/sup>, J. Cui<sup>12<\/sup>, L. Wang<sup>13<\/sup>, X. Chen<sup>14<\/sup>, X. Li<sup>15<\/sup>, Z. Wang<sup>16<\/sup>, Q. Wang<sup>17<\/sup>, J. He<sup>18<\/sup>, M. Wang<sup>19<\/sup>, L. Qian<sup>20<\/sup>, H. Hamidi<sup>21<\/sup>, S. Li<sup>2<\/sup>, M. Ballinger<sup>21<\/sup>, D. S. Shames<sup>21<\/sup>, M. Srivastava<sup>21<\/sup>; <br\/><sup>1<\/sup>Tongji University, Shanghai, China, <sup>2<\/sup>Translational Medicine (Genentech), Roche (China) Holding Ltd, Shanghai, China, <sup>3<\/sup>Cancer Center, Union Hospital of Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China, <sup>4<\/sup>Department of Respiratory Medicine, Harbin Medical University Cancer Hospital, Harbin, China, <sup>5<\/sup>Proton Center, Shandong Cancer Hospital, Jinan, Shandong, China, <sup>6<\/sup>Department of Thoracic Oncology, Fudan University Shanghai Cancer Center, Shanghai, China, <sup>7<\/sup>Department of Internal Medicine Oncology, First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China, <sup>8<\/sup>Zhejiang Cancer Hospital, Hangzhou; Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Zhejiang, China, <sup>9<\/sup>Department of Thoracic Oncology, Jilin Cancer Hospital, Changchun, China, <sup>10<\/sup>Department of Oncology, Sir Run Run Shaw Hospital, Zhejiang University, Hangzhou, China, <sup>11<\/sup>Department of Respiratory Medicine, Nan Tong Tumor Hospital, Nantong, China, <sup>12<\/sup>Department of Oncology, The First Hospital of Jilin University, Changchun, China, <sup>13<\/sup>Department of Oncology, Nanjing Drum Tower Hospital & The Affiliated Hospital of Nanjing University Medical School, Nanjing, China, <sup>14<\/sup>Department of Oncology, Fuzhou General Hospital, PLA Nanjing Military Area Command, Fuzhou, Fujian, China, <sup>15<\/sup>Department of Thoracic Medicine, Liaoning Cancer Hospital & Institute, Shenyang, China, <sup>16<\/sup>Department of Thoracic Oncology, Beijing Cancer Hospital, Beijing, China, <sup>17<\/sup>Department of Respiratory Medicine, The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, China, <sup>18<\/sup>Department of Thoracic Surgery, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China, <sup>19<\/sup>Department of Respiratory and Critical Care Medicine, Peking Union Medical College Hospital, Beijing, China, <sup>20<\/sup>Product Development, Roche (China) Holding Ltd, Shanghai, China, <sup>21<\/sup>Translational Medicine, Genentech, South San Francisco, CA","CSlideId":"","ControlKey":"6a68aa8d-883c-4386-9d4d-fa3ff6ccb5d7","ControlNumber":"10445","DisclosureBlock":"<b>&nbsp;C. Zhou, <\/b> <br><b>Innovent Biologics<\/b> Other, consulting fees. <br><b>Hengrui<\/b> Other, consulting fees. <br><b>Qilu<\/b> consulting fees. <br><b>TopAlliance Biosciences<\/b> Other, consulting fees. <br><b>Lily China<\/b> Other, Payment or honoraria for lectures,\u000d\u000apresentations, speakers bureaus, manuscript writing or educational events. <br><b>Sanofi<\/b> Other, Payment or honoraria for lectures,\u000d\u000apresentations, speakers bureaus, manuscript writing or educational events. <br><b>Boehringer Ingelheim<\/b> Other, Payment or honoraria for lectures,\u000d\u000apresentations, speakers bureaus, manuscript writing or educational events. <br><b>Roche<\/b> Other, Payment or honoraria for lectures,\u000d\u000apresentations, speakers bureaus, manuscript writing or educational events. <br><b>Merck Sharp & Dohme<\/b> Other, Payment or honoraria for lectures,\u000d\u000apresentations, speakers bureaus, manuscript writing or educational events. <br><b>Qilu<\/b> Other, Payment or honoraria for lectures,\u000d\u000apresentations, speakers bureaus, manuscript writing or educational events. <br><b>Hengrui<\/b> Other, Payment or honoraria for lectures,\u000d\u000apresentations, speakers bureaus, manuscript writing or educational events. <br><b>Innovent Biologics<\/b> Other, Payment or honoraria for lectures,\u000d\u000apresentations, speakers bureaus, manuscript writing or educational events. <br><b>Alice<\/b> Other, Payment or honoraria for lectures,\u000d\u000apresentations, speakers bureaus, manuscript writing or educational events. <br><b>C-Stone<\/b> Other, Payment or honoraria for lectures,\u000d\u000apresentations, speakers bureaus, manuscript writing or educational events. <br><b>LUYE Pharma<\/b> Other, Payment or honoraria for lectures,\u000d\u000apresentations, speakers bureaus, manuscript writing or educational events. <br><b>TopAlliance Biosciences<\/b> Other, Payment or honoraria for lectures,\u000d\u000apresentations, speakers bureaus, manuscript writing or educational events. <br><b>Amoy Diagnostics<\/b> Other, Payment or honoraria for lectures,\u000d\u000apresentations, speakers bureaus, manuscript writing or educational events. <br><b>AnHeart<\/b> Other, Payment or honoraria for lectures,\u000d\u000apresentations, speakers bureaus, manuscript writing or educational events. <br><b>C. Sun, <\/b> <br><b>Roche\/Genentech<\/b> Employment. <br><b>S. Huang, <\/b> <br><b>Roche<\/b> Employment, Stock.<br><b>X. Dong, <\/b> None..<br><b>G. Chen, <\/b> None..<br><b>Z. Wang, <\/b> None..<br><b>X. Wu, <\/b> None..<br><b>Y. Yao, <\/b> None..<br><b>Y. Zhang, <\/b> None..<br><b>Y. Cheng, <\/b> None..<br><b>H. Pan, <\/b> None..<br><b>X. Zhang, <\/b> None..<br><b>J. Cui, <\/b> None..<br><b>L. Wang, <\/b> None..<br><b>X. Chen, <\/b> None..<br><b>X. Li, <\/b> None..<br><b>Z. Wang, <\/b> None..<br><b>Q. Wang, <\/b> None..<br><b>J. He, <\/b> None..<br><b>M. Wang, <\/b> None.&nbsp;<br><b>L. Qian, <\/b> <br><b>Roche\/Genentech<\/b> Employment. <br><b>H. Hamidi, <\/b> <br><b>Genentech<\/b> Employment. <br><b>S. Li, <\/b> <br><b>Roche<\/b> Employment. <br><b>M. Ballinger, <\/b> <br><b>Genentech, Inc<\/b> Travel. <br><b>Roche<\/b> Stock, Stock Option. <br><b>Internal Monitoring Committee, SKYSCRAPER-11<\/b> Other, Participation on a Data Safety Monitoring Board or Advisory Board. <br><b>D. S. Shames, <\/b> <br><b>Roche\/Genentech<\/b> Employment. <br><b>Roche\/Genentech<\/b> Stock, Stock Option. <br><b>M. Srivastava, <\/b> <br><b>Genentech<\/b> Employment. <br><b>Roche<\/b> Stock, Stock Option.","End":"4\/9\/2024 12:30:00 PM","HasWebcast":null,"Highlights":[],"Id":"11595","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":null,"OtherContent":null,"PlayerUrl":"https:\/\/files.abstractsonline.com\/SUPT\/101\/10517\/cfg-cattendee-cslide-player-view-content-embargoed.png","PlayerUrlReason":"Content is embargoed at this time.","PositionInSession":"5","PosterboardNumber":"6","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"CT235","PresenterBiography":null,"PresenterDisplayName":"Caicun Zhou, PhD","PresenterKey":"49eea442-d77c-48ed-80ca-cb57b8f727ea","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"CT235. RNA-seq molecular subtypes and gene expression signatures in the phase 3 IMpower151 study of 1L bevacizumab + pemetrexed\/paclitaxel &#177; atezolizumab in metastatic NSCLC","SearchResultFooter":"","SearchResultHeader":"Apr  9 2024  9:00AM","SessionId":"618","SessionOnDemand":"False","SessionTitle":"Phase III Clinical Trials","ShowChatLink":"false","Start":"4\/9\/2024 9:00:00 AM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"RNA-seq molecular subtypes and gene expression signatures in the phase 3 IMpower151 study of 1L bevacizumab + pemetrexed\/paclitaxel &#177; atezolizumab in metastatic NSCLC","Topics":null,"cSlideId":""},{"Abstract":"Abstract is embargoed at this time.","Actions":[{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Late Breaking and Clinical Trials","AdditionalFields":[{"Key":"Topics","Value":"++PL06-01 Phase III adult clinical trials,,"},{"Key":"Keywords","Value":"Durvalumab,Neoadjuvant,Resectable,ctDNA,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":null,"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":"<b>D. Gale<\/b><sup>1<\/sup>, Z. Zhu<sup>2<\/sup>, Z. Lai<sup>3<\/sup>, M. Reck<sup>4<\/sup>, D. Harpole<sup>5<\/sup>, J. M. Taube<sup>6<\/sup>, T. Mitsudomi<sup>7<\/sup>, M. Hochmair<sup>8<\/sup>, T. Winder<sup>9<\/sup>, L. Urbán<sup>10<\/sup>, J. Rodriguez-Cid<sup>11<\/sup>, Q. Chu<sup>12<\/sup>, J. Chaft<sup>13<\/sup>, R. Stewart<sup>1<\/sup>, D. Hodgson<sup>1<\/sup>, G. J. Doherty<sup>1<\/sup>, J. V. Heymach<sup>14<\/sup>; <br\/><sup>1<\/sup>AstraZeneca, Cambridge, United Kingdom, <sup>2<\/sup>AstraZeneca, Gaithersburg, MD, <sup>3<\/sup>AstraZeneca, Waltham, MD, <sup>4<\/sup>Lung Clinic Grosshansdorf, Airway Research Center North, German Center for Lung Research, Grosshansdorf, Germany, <sup>5<\/sup>Department of Surgery, Duke University Medical Center, Durham, NC, <sup>6<\/sup>Bloomberg–Kimmel Institute for Cancer Immunotherapy, Johns Hopkins Kimmel Cancer Center, Baltimore, MD, <sup>7<\/sup>Division of Thoracic Surgery, Department of Surgery, Kindai University Faculty of Medicine, Osaka-Sayama, Japan, <sup>8<\/sup>Department of Respiratory and Critical Care Medicine, Karl Landsteiner Institute of Lung Research and Pulmonary Oncology, Klinik Floridsdorf, Vienna, Austria, <sup>9<\/sup>Internal Medicine II, Landeskrankenhaus Feldkirch, Feldkirch, Austria, <sup>10<\/sup>Mátraháza University and Teaching Hospital, Mátraháza, Hungary, <sup>11<\/sup>Oncology Center, Medica Sur Hospital, Mexico City, Mexico, <sup>12<\/sup>Cross Cancer Institute, Edmonton, AB, Canada, <sup>13<\/sup>Memorial Sloan-Kettering Cancer Center and Weill Cornell Medical College, New York, NY, <sup>14<\/sup>Department of Thoracic\/Head and Neck Medical Oncology, The University of Texas, M.D. Anderson Cancer Center, Houston, TX","CSlideId":"","ControlKey":"cccd5d56-1e77-46b7-b185-b840cc85947b","ControlNumber":"9700","DisclosureBlock":"<b>&nbsp;D. Gale, <\/b> <br><b>AstraZeneca<\/b> Employment, Stock, Stock Option, Patent. <br><b>Z. Zhu, <\/b> <br><b>AstraZeneca<\/b> Employment. <br><b>Z. Lai, <\/b> <br><b>AstraZeneca<\/b> Employment, Stock. <br><b>M. Reck, <\/b> <br><b>Amgen<\/b> Travel, Other, Consulting fees, payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events, support for attending meetings and\/or travel. <br><b>AstraZeneca<\/b> Travel, Other, Consulting fees, payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events, support for attending meetings and\/or travel. <br><b>Beigene<\/b> Travel, Other, Consulting fees, payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events, support for attending meetings and\/or travel. <br><b>Boehringer-Ingelheim<\/b> Travel, Other, Consulting fees, payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events, support for attending meetings and\/or travel. <br><b>BMS<\/b> Travel, Other, Consulting fees, payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events, support for attending meetings and\/or travel. <br><b>Lilly<\/b> Travel, Other, Consulting fees, payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events, support for attending meetings and\/or travel. <br><b>Merck<\/b> Travel, Other, Consulting fees, payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events, support for attending meetings and\/or travel. <br><b>MSD<\/b> Travel, Other, Consulting fees, payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events, support for attending meetings and\/or travel. <br><b>Mirati<\/b> Travel, Other, Consulting fees, payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events, support for attending meetings and\/or travel. <br><b>Novartis<\/b> Travel, Other, Consulting fees, payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events, support for attending meetings and\/or travel. <br><b>GSK<\/b> Travel, Other, Consulting fees, payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events, support for attending meetings and\/or travel. <br><b>Pfizer<\/b> Travel, Other, Consulting fees, payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events, support for attending meetings and\/or travel. <br><b>Roche<\/b> Travel, Other, Consulting fees, payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events, support for attending meetings and\/or travel. <br><b>Regeneron<\/b> Travel, Other, Consulting fees, payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events, support for attending meetings and\/or travel. <br><b>Sanofi<\/b> Travel, Other, Consulting fees, payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events, support for attending meetings and\/or travel. Participation on a Data Safety Monitoring Board or Advisory Board.. <br><b>Daiichi-Sankyo<\/b> Travel, Other, Consulting fees, payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events, support for attending meetings and\/or travel. Participation on a Data Safety Monitoring Board or Advisory Board.. <br><b>Janssen<\/b> Travel, Other, Consulting fees, payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events, support for attending meetings and\/or travel. <br><b>D. Harpole, <\/b> <br><b>AstraZeneca<\/b> Other, Scientific advisory board. <br><b>J. M. Taube, <\/b> <br><b>Akoya<\/b> Stock Option, Grant\/Contract, Patent, Other, Ad Board\/Consulting. <br><b>BMS<\/b> Grant\/Contract, Other, Ad Board\/Consulting. <br><b>AstraZeneca<\/b> Other, Ad Board\/Consulting. <br><b>Merck<\/b> Other, Ad Board\/Consulting. <br><b>Regeneron<\/b> Other, Ad Board\/Consulting. <br><b>Lunaphore<\/b> Other, Ad Board\/Consulting. <br><b>Elephas<\/b> Other, Ad Board\/Consulting. <br><b>Compugen<\/b> Other, Ad Board\/Consulting. <br><b>Akoya Biosciences<\/b> Other, Reagents and equipment. <br><b>T. Mitsudomi, <\/b> <br><b>AstraZeneca<\/b> Grant\/Contract. <br><b>M. Hochmair, <\/b> <br><b>Roche<\/b> Other, Invited speaker and advisory board. <br><b>BMS<\/b> Other, Invited speaker and advisory board. <br><b>MSD<\/b> Other, Invited speaker and advisory board. <br><b>Lilly<\/b> Other, Invited speaker and advisory board. <br><b>AMGEN<\/b> Other, Invited speaker and advisory board. <br><b>Takeda<\/b> Other, Invited speaker and advisory board.<br><b>T. Winder, <\/b> None..<br><b>L. Urbán, <\/b> None..<br><b>J. Rodriguez-Cid, <\/b> None.&nbsp;<br><b>Q. Chu, <\/b> <br><b>AstraZeneca<\/b> Grant\/Contract. <br><b>J. Chaft, <\/b> <br><b>Janssen<\/b> Independent Contractor. <br><b>Beigene<\/b> Grant\/Contract. <br><b>AstraZeneca<\/b> Independent Contractor, Grant\/Contract. <br><b>BMS<\/b> Independent Contractor, Grant\/Contract. <br><b>Merck<\/b> Independent Contractor, Grant\/Contract. <br><b>Genentech<\/b> Independent Contractor, Grant\/Contract. <br><b>Arcus Biosciences<\/b> Independent Contractor. <br><b>Guardant Health<\/b> Independent Contractor. <br><b>Novartis<\/b> Grant\/Contract. <br><b>R. Stewart, <\/b> <br><b>AstraZeneca<\/b> Employment, Stock Option. <br><b>D. Hodgson, <\/b> <br><b>AstraZeneca<\/b> Employment, Stock, Stock Option. <br><b>G. J. Doherty, <\/b> <br><b>AstraZeneca<\/b> Employment, Stock. <br><b>J. V. Heymach, <\/b> <br><b>AstraZeneca<\/b> Grant\/Contract, Other, Consulting\/advisory board; principal investigator. <br><b>Mirati Therapeutics<\/b> Grant\/Contract, Other, Consulting\/advisory board; principal investigator. <br><b>Eli Lilly & Co<\/b> Other, Consulting\/advisory board. <br><b>Janssen Pharmaceuticals<\/b> Other, Consulting\/advisory board. <br><b>Boehringer-Ingelheim Pharmaceuticals<\/b> Grant\/Contract, Other, Consulting\/advisory board; principal investigator. <br><b>Regeneron<\/b> Other, Consulting\/advisory board. <br><b>Takeda Pharmaceuticals<\/b> Grant\/Contract, Other, Consulting\/advisory board; principal investigator. <br><b>BerGenBio<\/b> Other, Consulting\/advisory board. <br><b>Jazz Pharmaceuticals<\/b> Other, Consulting\/advisory board. <br><b>Curio Science<\/b> Other, Consulting\/advisory board. <br><b>Novartis<\/b> Other, Consulting\/advisory board. <br><b>BioAlta<\/b> Other, Consulting\/advisory board. <br><b>Sanofi<\/b> Other, Consulting\/advisory board. <br><b>Spectrum Pharmaceuticals<\/b> Grant\/Contract, Other, Consulting\/advisory board; principal investigator; licensing fees; royalties. <br><b>GlaxoSmithKline<\/b> Other, Consulting\/advisory board. <br><b>EMD Serono<\/b> Other, Consulting\/advisory board. <br><b>BluePrint Medicine<\/b> Other, Consulting\/advisory board. <br><b>Chugai Pharmaceutical<\/b> Other, Consulting\/advisory board. <br><b>The University of Texas MD Anderson Cancer Center<\/b> Employment. <br><b>Wojcicicki Foundation<\/b> Other, Chair.","End":"4\/9\/2024 12:30:00 PM","HasWebcast":null,"Highlights":[],"Id":"11598","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":null,"OtherContent":null,"PlayerUrl":"https:\/\/files.abstractsonline.com\/SUPT\/101\/10517\/cfg-cattendee-cslide-player-view-content-embargoed.png","PlayerUrlReason":"Content is embargoed at this time.","PositionInSession":"6","PosterboardNumber":"9","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"CT238","PresenterBiography":null,"PresenterDisplayName":"Davina Gale, BS;PhD","PresenterKey":"f4e40beb-82cb-40ef-9aaa-74f4127b2ccb","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"CT238. Associations of ctDNA levels during neoadjuvant treatment with pathological response in patients with resectable NSCLC from the phase 3 AEGEAN trial","SearchResultFooter":"","SearchResultHeader":"Apr  9 2024  9:00AM","SessionId":"618","SessionOnDemand":"False","SessionTitle":"Phase III Clinical Trials","ShowChatLink":"false","Start":"4\/9\/2024 9:00:00 AM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"Associations of ctDNA levels during neoadjuvant treatment with pathological response in patients with resectable NSCLC from the phase 3 AEGEAN trial","Topics":null,"cSlideId":""},{"Abstract":"Abstract is embargoed at this time.","Actions":[{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Late Breaking and Clinical Trials","AdditionalFields":[{"Key":"Topics","Value":"++CT06-01 Phase III adult clinical trials,,"},{"Key":"Keywords","Value":"Lung cancer: non-small cell,Adjuvant,Immune checkpoint blockade,,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":null,"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":"<b>J. Wang<\/b><sup>1<\/sup>, Y. Fan<sup>2<\/sup>, J. Fang<sup>3<\/sup>, J. He<sup>4<\/sup>, Y. Liu<sup>5<\/sup>, M. Tao<sup>6<\/sup>, N. Altorki<sup>7<\/sup>, E. Felip<sup>8<\/sup>, H. Wakelee<sup>9<\/sup>, E. Vallieres<sup>10<\/sup>, R. Belleli<sup>11<\/sup>, V. McNally<sup>12<\/sup>, E. Bennett<sup>13<\/sup>, B. J. Gitlitz<sup>14<\/sup>, C. Zhou<sup>15<\/sup>; <br\/><sup>1<\/sup>Cancer Hospital, Chinese Academy of Medical Sciences, Beijing, China, <sup>2<\/sup>Zhejiang Cancer Hospital, Hanzou, China, <sup>3<\/sup>Beijing Cancer Hospital, Beijing, China, <sup>4<\/sup>The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China, <sup>5<\/sup>First Hospital, China Medical University, Shenyang, China, <sup>6<\/sup>The First Affiliated Hospital of Soochow University, Jiangsu, China, <sup>7<\/sup>NewYork-Presbyterian Hospital, Weill Cornell Medicine, New York, NY, <sup>8<\/sup>Vall d’Hebron University Hospital, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain, <sup>9<\/sup>Stanford University School of Medicine\/Stanford Cancer Institute, Stanford, CA, <sup>10<\/sup>Swedish Cancer Institute, Seattle, WA, <sup>11<\/sup>F. Hoffmann-La Roche Ltd, Basel, Switzerland, <sup>12<\/sup>Roche Products Ltd, Welwyn Garden City, United Kingdom, <sup>13<\/sup>Genentech Inc, South San Francisco, CA, <sup>14<\/sup>Genentech, Inc., South San Francisco, CA, <sup>15<\/sup>Tongji University Affiliated Shanghai Pulmonary Hospital, Shanghai, China","CSlideId":"","ControlKey":"828e3234-e590-446f-bf5f-ab1326ffdb53","ControlNumber":"10682","DisclosureBlock":"<b>&nbsp;J. Wang, <\/b> <br><b>Roche<\/b> Other, Medical Writing Support. <br><b>Y. Fan, <\/b> <br><b>Roche<\/b> Other, Medical Writing Support. <br><b>J. Fang, <\/b> <br><b>Roche<\/b> Other, Medical Writing Support. <br><b>J. He, <\/b> <br><b>Roche<\/b> Other, Medical Writing Support. <br><b>Y. Liu, <\/b> <br><b>Roche<\/b> Other, Medical Writing Support. <br><b>M. Tao, <\/b> <br><b>Roche<\/b> Other, Medical Writing Support. <br><b>N. Altorki, <\/b> <br><b>Roche<\/b> Other, Medical Writing Support. <br><b>E. Felip, <\/b> <br><b>Amgen<\/b> Other, Invited Speaker. <br><b>AstraZeneca<\/b> Travel, Other, Invited Speaker, Advisory Board. <br><b>Bristol Myers Squibb<\/b> Other, Invited Speaker, Advisory Board. <br><b>Daiichi Sankyo<\/b> Other, Invited Speaker, Advisory Board. <br><b>Eli Lilly<\/b> Other, Invited Speaker, Advisory Board. <br><b>Roche<\/b> Travel, Other, Medical Writing Support, Invited Speaker, Advisory Board. <br><b>Janssen<\/b> Travel, Other, Invited Speaker, Advisory Board. <br><b>Medical Trends<\/b> Other, Invited Speaker. <br><b>Medscape<\/b> Other, Invited Speaker. <br><b>Merck Serono<\/b> Other, Invited Speaker, Advisory Board. <br><b>Merck Sharpe & Dohme<\/b> Other, Invited Speaker, Advisory Board. <br><b>PeerVoice<\/b> Invited Speaker. <br><b>Pfizer<\/b> Other, Invited Speaker. <br><b>Sanofi<\/b> Other, Invited Speaker, Advisory Board. <br><b>Takeda<\/b> Other, Invited Speaker, Advisory Board. <br><b>Touch Oncology<\/b> Other, Invited Speaker. <br><b>AbbVie<\/b> Other, Advisory Board. <br><b>Bayer<\/b> Other, Advisory Board. <br><b>Beigene<\/b> Other, Advisory Board. <br><b>Boehringer Ingelheim<\/b> Other, Advisory Board. <br><b>H. Wakelee, <\/b> <br><b>IOBiotech<\/b> Independent Contractor. <br><b>Mirati<\/b> Independent Contractor. <br><b>BMS<\/b> Grant\/Contract, Other, Unpaid advisor. <br><b>Roche\/Genentech<\/b> Grant\/Contract, Other, Medical Writing Support, Unpaid advisor. <br><b>Merck<\/b> Grant\/Contract, Other, Unpaid advisor. <br><b>AstraZeneca<\/b> Grant\/Contract, Other, Unpaid advisor. <br><b>Bayer<\/b> Grant\/Contract. <br><b>Helsinn<\/b> Grant\/Contract. <br><b>SeaGen<\/b> Grant\/Contract. <br><b>Xcovery<\/b> Grant\/Contract. <br><b>E. Vallieres, <\/b> <br><b>Roche<\/b> Other, Medical Writing Support. <br><b>R. Belleli, <\/b> <br><b>Roche<\/b> Employment, Stock. <br><b>V. McNally, <\/b> <br><b>Roche<\/b> Employment, Stock. <br><b>E. Bennett, <\/b> <br><b>Genentech\/Roche<\/b> Employment, Stock. <br><b>B. J. Gitlitz, <\/b> <br><b>Genentech\/Roche<\/b> Employment, Stock. <br><b>C. Zhou, <\/b> <br><b>Innovent Biologics<\/b> Other, Consulting fees, Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events. <br><b>Hengrui<\/b> Other, Consulting fees, Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events. <br><b>Qilu<\/b> Other, Consulting fees, Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events. <br><b>TopAlliance Biosciences<\/b> Other, Consulting fees, Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events. <br><b>Lily China<\/b> Other, Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events. <br><b>Sanofi<\/b> Other, Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events. <br><b>Boehringer Ingelheim<\/b> Other, Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events. <br><b>Roche<\/b> Other, Medical Writing Support, Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events. <br><b>Merck Sharpe & Dohme<\/b> Other, Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events. <br><b>Alice<\/b> Other, Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events. <br><b>C-Stone<\/b> Other, Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events. <br><b>LUYE Pharma<\/b> Other, Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events. <br><b>Amoy Diagnostics<\/b> Other, Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events. <br><b>AnHeart<\/b> Other, Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events.","End":"4\/9\/2024 12:30:00 PM","HasWebcast":null,"Highlights":[],"Id":"11599","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":null,"OtherContent":null,"PlayerUrl":"https:\/\/files.abstractsonline.com\/SUPT\/101\/10517\/cfg-cattendee-cslide-player-view-content-embargoed.png","PlayerUrlReason":"Content is embargoed at this time.","PositionInSession":"7","PosterboardNumber":"10","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"CT239","PresenterBiography":null,"PresenterDisplayName":"Angel Yutig","PresenterKey":"6d4c90c1-9826-4518-a1af-05d4e9de89b8","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"CT239. IMpower010: Updated overall survival and safety results from Asian patients in a Phase III study of adjuvant atezolizumab vs best supportive care in resected stage IB-IIIA NSCLC","SearchResultFooter":"","SearchResultHeader":"Apr  9 2024  9:00AM","SessionId":"618","SessionOnDemand":"False","SessionTitle":"Phase III Clinical Trials","ShowChatLink":"false","Start":"4\/9\/2024 9:00:00 AM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"IMpower010: Updated overall survival and safety results from Asian patients in a Phase III study of adjuvant atezolizumab vs best supportive care in resected stage IB-IIIA NSCLC","Topics":null,"cSlideId":""}]